Acyclovir
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ACYCLOVIR |
|---|---|
| Type | Drug |
| Aliases | ZoviraxАцикловір |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-MM-2025 |
Drug Facts
| Class | Nucleoside analogue antiviral (acyclic guanosine) |
|---|---|
| Mechanism | Selectively phosphorylated by viral thymidine kinase to acyclovir monophosphate, then by host kinases to acyclovir triphosphate, which inhibits viral DNA polymerase and terminates viral DNA chain elongation. Active against HSV-1, HSV-2, VZV; modest activity against EBV, CMV. |
| Typical dosing | 400 mg PO twice daily for HSV/VZV prophylaxis during proteasome inhibitor therapy |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
HSV/VZV prophylaxis is mandatory during proteasome inhibitor therapy (bortezomib, carfilzomib, ixazomib) due to substantially increased risk of herpes zoster reactivation. Renal dose adjustment required if CrCl <50 mL/min. Valacyclovir (500 mg PO daily) is an acceptable prodrug alternative with better bioavailability.
Used By
Supportive Care
SUP-HSV-PROPHYLAXIS- HSV / VZV prophylaxis during proteasome inhibitor therapy